Immunome Inc. (IMNM)
6.24
-0.49 (-7.28%)
At close: Apr 01, 2025, 3:07 PM
Company Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease.
The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system.
It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Immunome Inc.
| Country | United States |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 118 |
| CEO | Dr. Clay B. Siegall Ph.D. |
Contact Details
Address: 665 Stockton Drive Exton, Pennsylvania United States | |
| Website | https://immunome.com |
Stock Details
| Ticker Symbol | IMNM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001472012 |
| CUSIP Number | 45257U108 |
| ISIN Number | US45257U1088 |
| Employer ID | 77-0694340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Clay B. Siegall Ph.D. | Chairman, President & Chief Executive Officer |
| Max Rosett | Chief Financial Officer |
| Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel & Corporate Secretary |
| Dr. Jack Higgins Ph.D. | Chief Scientific Officer |
| Dr. Philip Tsai | Chief Technical Officer |
| Dr. Robert J. Lechleider M.D. | Chief Medical Officer |
| Kinney Horn | Chief Business Officer |
| Roee Shahar | Executive Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 4 | Filing |
| Mar 26, 2025 | 4 | Filing |
| Mar 26, 2025 | 4 | Filing |
| Mar 25, 2025 | 4 | Filing |
| Mar 25, 2025 | 4 | Filing |
| Mar 19, 2025 | S-8 | Filing |
| Mar 19, 2025 | 10-K | Annual Report |
| Mar 19, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 04, 2025 | SCHEDULE 13D/A | [Amend] Filing |